Faculty & Staff Scholarship
2010

Kaempferol enhances cisplatin's effect on ovarian cancer cells
through promoting apoptosis caused by down regulation of cMyc
Haitao Luo
Alderson-Broaddus College

Matthew K. Daddysman
Alderson-Broaddus College

Gary O. Rankin
Marshall University

Bing-Hua Jiang
West Virginia University

Yi C. Chen
Alderson-Broaddus College

Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications

Digital Commons Citation
Luo, Haitao; Daddysman, Matthew K.; Rankin, Gary O.; Jiang, Bing-Hua; and Chen, Yi C., "Kaempferol
enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down
regulation of cMyc" (2010). Faculty & Staff Scholarship. 2803.
https://researchrepository.wvu.edu/faculty_publications/2803

This Article is brought to you for free and open access by The Research Repository @ WVU. It has been accepted
for inclusion in Faculty & Staff Scholarship by an authorized administrator of The Research Repository @ WVU. For
more information, please contact ian.harmon@mail.wvu.edu.

Luo et al. Cancer Cell International 2010, 10:16
http://www.cancerci.com/content/10/1/16

Open Access

PRIMARY RESEARCH

Kaempferol enhances cisplatin's effect on ovarian
cancer cells through promoting apoptosis caused
by down regulation of cMyc
Primary research

Haitao Luo1, Matthew K Daddysman1, Gary O Rankin3, Bing-Hua Jiang2 and Yi C Chen*1

Abstract
Background: Ovarian cancer is one of the most significant malignancies in the western world. Studies showed that
Ovarian cancers tend to grow resistance to cisplatin treatment. Therefore, new approaches are needed in ovarian
cancer treatment. Kaempferol is a dietary flavonoid that is widely distributed in fruits and vegetables, and
epidemiology studies have revealed a protective effect of kaempferol against ovarian cancer risk. Our early studies also
found that kaempferol is effective in reducing vascular endothelial growth factor (VEGF) expression in ovarian cancer
cells. In this study, we investigated kaempferol's effects on sensitizing ovarian cancer cell growth in response to
cisplatin treatment.
Results: Ten chemicals were screened for sensitizing OVCAR-3 ovarian cancer cell growth in response to cisplatin
treatment. For kaempferol, which shows a significant synergistic interaction with cisplatin, expression of ABCC1, ABCC5,
ABCC6, NFkB1, cMyc, and CDKN1A genes was further examined. For cisplatin/kaempferol treatments on OVCAR-3
cancer cells, the mRNA levels of ABCC1, ABCC5, and NFkB1 did not change. However, significant inhibition of ABCC6
and cMyc mRNA levels was observed for the cisplatin/kaempferol combined treatment. The CDKN1A mRNA levels
were significantly up-regulated by cisplatin/kaempferol treatment. A plot of CDKN1A mRNA levels against that of cMyc
gene further revealed a reverse, linear relationship, proving cMyc's regulation on CDKN1A gene expressions. Our work
found that kaempferol works synergistically with cisplatin in inhibiting ovarian cancer cell viability, and their inhibition
on cell viabilities was induced through inhibiting ABCC6 and cMyc gene transcription. Apoptosis assay showed the
addition of 20 μM kaempferol to the cisplatin treatment induces the apoptosis of the cancer cells.
Conclusions: Kaempferol enhances the effect of cisplatin through down regulation of cMyc in promoting apoptosis of
ovarian cancer cells. As a dietary component, kaempferol sensitizes ovarian cancer cells to cisplatin treatment and
deserves further studies for possible applications in chemotherapy of ovarian cancers.
Background
Ovarian cancer is one of the most important diseases for
women in Western countries. It is the fifth leading cause
of cancer-related deaths [1]. Treatment of ovarian cancers
usually involves surgery and chemotherapy. The combination of cisplatin and paclitaxel as a chemotherapeutic
regimen has improved the survival of ovarian cancer
patients. However, the results are not satisfying because
of drug resistance developed by cancer cells [2]. The cancer frequently progresses after the treatment and the
majority of ovarian cancer patients die as cancer later
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relapses [3]. Therefore, it is important to identify new
approaches for the treatment of ovarian cancer.
Flavonoids are polyphenolic natural compounds which
are present in a wide variety of fruits and vegetables [4]
and are protective against some forms of cancer [5]. It has
been reported that dietary flavonoids reduce the risks of
humans to cardiovascular disease [6], prostate cancer [7],
colorectal cancer [8], and renal cancer [4]. Flavonoids
were also reported to inhibit cell growth and proliferation
[9] and induce cell toxicity [10] in cancer cells.
Cisplatin (cis-diamminedichloroplatinum(II)) is commonly used in the treatment of various cancers. Cisplatin
is activate inside the cell and reacts with guanine residues
in DNA. The binding of cisplatin to DNA changes the
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secondary structure of DNA and consequently the
metabolism of the cell. The exact mechanism by which
cisplatin influences the metabolism of the cell and consequently cell growth is unclear [11].
Several genes have been reported to potentially play a
role in cisplatin resistance. The ABCC1, ABCC5, and
ABCC6 genes are members of the ABCC family of membrane transport proteins. These genes have been implicated in drug resistance of a variety of anticancer drugs
including platinum based drugs such as cisplatin. Inhibition of these genes is ideal to reduce the efflux of anticancer drugs out of the cell [12]. The NFκB1 gene is a subunit
of the NFκB gene, an important regulator of genes controlling a variety of cell survival process including proliferation and apoptosis. Activation of the NFκB gene has
been implicated in many human cancers [13]. The genes
cMyc and CDKN1A are also important regulators of cell
proliferation and apoptosis. However, their role in cisplatin resistance is unclear.
In this study, we investigated the sensitization effects of
eight flavonoids (luteolin, genistein, quercetin, kaempferol, taxifolin, rutin hydrate, naringin, and apigenin), and
two forms of vitamin E (tocopherol and tocopherol succinate) on the cisplatin induced killing of cells in the ovarian cancer cell line OVCAR-3. To measure the
sensitization effect we used a novel statistical model to
distinguish between true sensitization of the cells to cisplatin and the additive effect of the combined toxicity of
the sensitization chemical and cisplatin. For any chemicals that showed a sensitization effect we further measured the effect of the cisplatin-chemical combination on
the expression of ABCC1, ABCC5, ABCC6, NFκB1, cMyc
and CDKN1A genes.

Results
Kaempferol synergistically enhances cisplatin's effect on
inhibiting proliferation of OVCAR-3 cancer cells

All 10 chemicals, including 8 flavonoids and 2 α-tocopherols, were tested at 20-μM concentration for their additive or synergistic effects with cisplatin on OVCAR-3
cancer cells. As shown in Figure 1, OVCAR-3 cancer cells
are relatively resistant to cisplatin treatment, remaining
88.1-95.3% (or 1.945-1.979 when logged) viability at 80μM cisplatin concentration. The effects of test chemicals
alone (at 20-μM) vary from no effect (99% for taxifolin) to
moderate effect (67% for rutin hydrate). With the exception of taxifolin, co-treatment with cisplatin and test
chemicals was more effective inhibiting cancer cell proliferation than cisplatin alone, although the majority of
these combined effects are additive (p > 0.05 for coefficients of Cisplatin*Drug, Table 1). However, for kaempferol and α-tocopherol succinate, the resistance to
cisplatin in OVCAR-3 cells was reduced, with the cell viability down-regulated to 68.4% (1.835 when logged) and
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71.3% (1.853 when logged), respectively. The slope of cisplatin treatment, by linear regression analysis, is changed
from -0.012 to -0.070 by co-treatment with 20-μM kaempferol, and from -0.019 to -0.051 by co-treatment with
20-μM α-tocopherol succinate, demonstrating a significant sensitization (p = 0.001 for kaempferol and 0.015 for
α-tocopherol succinate). The goodness of fit (R2 = 0.901
for kaempferol and 0.891 for α-tocopherol succinate) in
these models suggests a successful regression on logged
viability data with kaempferol and α-tocopherol succinate
co-treatments (Table 1).
Kaempferol enhances cisplatin's effect on gene
transcription for ABCC6, cMyc and CDKN1A in OVCAR-3
cancer cells

Because kaempferol sensitizes OVCAR-3 cancer cells'
response to cisplatin treatment, the effect on gene
expression by cisplatin and/or kaempferol was further
evaluated by analyzing mRNA levels of ABCC1, ABCC5,
ABCC6, NFκB1, cMyc and CDKN1A genes. As shown in
Figure 2, cisplatin treatment, with or without kaempferol,
does not alter mRNA levels significantly for ABCC1,
ABCC5, and NFκB1 genes. However, cisplatin decreased
ABCC6 and cMyc mRNA levels in a dose-dependent
manner, with a remaining mRNA level of about 58% at
80-μM concentration (p < 0.05). Kaempferol treatment
also inhibited ABCC6 and cMyc genes transcription
down to 68% (p < 0.01). Combination of kaempferol with
40-μM cisplatin further inhibited ABCC6 and cMyc
genes mRNA levels down to 65% (p < 0.05), and with 80μM cisplatin leads to the lowest mRNA level of 55% for
cMyc(p < 0.01), although no enhancement is observed for
ABCC6 gene at 80-μM cisplatin concentration. For the
CDKN1A gene, cisplatin increased mRNA levels dosedependently, reaching 818.7% at 80-μM concentration (p
< 0.05), while kaempferol failed to increase CDKN1A
mRNA level significantly (p = 0.891). However, combination of the two chemicals brings the CDKN1A mRNA
level up to 1064.7% (p < 0.01). Due to the known regulation of the CDKN1A gene expression by cMyc, the relationship between the two genes was further examined.
The mRNA levels of CDKN1A were plotted against cMyc
in a linear scale and a linear relationship was observed
between cMyc and CDKN1A mRNA levels, regardless of
kaempferol treatment (Figure 3). The two sets of data
were pooled for correlation analysis, and the Pearson correlation coefficient is -0.649, demonstrating a strong negative association (p < 0.01).
Kaempferol promotes apoptosis in OVCAR-3 cancer cells
treated with cisplatin

Cisplatin and kaempferol were also tested for their effects
in inducing apoptosis in OVCAR-3 cancer cells. Caspase3 levels in OVCAR-3 cells range from 5-13 pg/μg-Total
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Figure 1 Effect on cell proliferation in OVCAR-3 cancer cells. OVCAR-3 cells (8 × 103) were seeded into wells in 96-well cell culture microplates,
incubated for 16 hours, and treated with 0, 40, and 80-μM Cisplatin with or without other chemicals of 20 μM for 24 hours in triplicates. Cell viability
was analyzed with MTS-based assay, normalized as percent of control, logged and fitted to linear regression models to check cisplatin and other
chemicals' effects on cell proliferation, and their interactions. Data represents MEAN ± SE from 3 independent experiments.

Protein (TP), but showed considerable inter-experiment
variances. Caspase-3 levels were expressed as percent of
control within each experiment and plotted in logarithmic scale for linear regression analysis. As shown in Figure 4, cisplatin treatment alone, up to 80 μM, does not
cause any noticeable changes in caspase-3 levels as compared to the 7.4 pg/μg-TP in control (p > 0.70), while a
20-μM kaempferol treatment raised caspase-3 levels to
8.2 pg/μg-TP. More importantly, when combined with
kaempferol treatment, cisplatin begins to have a dosedependent effect in inducing caspase-3 levels, a significant sensitization proven by linear regression analysis (p
< 0.05 for coefficient of Cisplatin*Kaempferol, R2 =
0.905). The caspase-3 level is 8.6 pg/μg-TP for cells
treated with 40-μM cisplatin and 20-μM kaempferol (p <
0.05) and 9.2 pg/μg-TP for cells treated with 80-μM cisplatin and 20-μM kaempferol, significantly higher than that
of control.

Discussion
There are many different chemotherapy agents for treating cancer. One of the most commonly used chemotherapy drugs is cisplatin. Cisplatin is commonly used in

cancers of the head, neck, bladder, ovary, and testis.
Unfortunately, many cancer cells are resistant to cisplatin
treatment or may become resistant with treatment. Currently the only way to overcome acquired resistance to
cisplatin in cancer cells is by increasing dosage, which
results in higher toxicity in normal body cells [14]. Resistance to cisplatin treatment can be due to lack of the p53
gene [15], by the activation of cell survival genes such as
nuclear factor-κB (NF-κB) [16], and by the reduced cellular concentration of cisplatin [14].
OVCAR-3 cells were found to be resistant to cisplatin
treatment with 88.1-95.3% viability at 80-μM cisplatin
concentration. Our previous studies found that flavonoids, including kaempferol, inhibit ovarian cancer cell
growth and VEGF expression [17]. Some flavonoids are
reported to have sensitization effects on cisplatin [15,18].
The 10 chemicals screened, varied in their viability suppression from light to moderate. Among the 10 chemicals
tested only kaempferol, a flavonoid, and α-tocopherol
succinate, a vitamin E derivative, significantly sensitized
OVCAR-3 cells to cisplatin treatment. With the exception of taxifolin, all of the combined treatments with cisplatin and the test chemical resulted in a more effective
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Table 1: Linear regression to analyze cisplatin and/or compound's effect on OVCAR-3 cell proliferation.
Kaempferol
R2

α-Tocopherol Succinate

0.901
B

Rutin Hydrate

0.891
Sig.

B

0.188
Sig.

B

Sig.

Constant

2.002

0.000

2.010

0.000

2.009

0.000

Cisplatin

-0.012

0.198

-0.019

0.040

-0.028

0.789

Compound

-0.022

0.238

-0.048

0.006

-0.237

0.221

Cispl. × Comp.

-0.058

0.001

-0.032

0.015

0.029

0.844

Apigenin
R2

Taxifolin

0.947
B

Luteolin

0.415
Sig.

B

0.841
Sig.

B

Sig.

Constant

2.008

0.000

2.009

0.000

2.010

0.000

Cisplatin

-0.015

0.119

-0.028

0.035

-0.019

0.076

Compound

-0.173

0.000

-0.003

0.902

-0.102

0.000

Cispl. × Comp.

0.0080

0.571

0.003

0.884

0.008

0.548

Naringin
R2

α-Tocopherol

0.296
B

Genistein

0.541
Sig.

B

0.885
Sig.

B

Sig.

Constant

2.009

0.000

2.010

0.000

2.010

0.000

Cisplatin

-0.028

0.306

-0.019

0.521

-0.019

0.086

Compound

-0.058

0.243

-0.062

0.253

-0.117

0.000

Cispl. × Comp.

0.001

0.989

-0.046

0.269

0.0001

0.994

Quercetin
R2

0.567
B

Sig.

Constant

2.010

0.000

Cisplatin

-0.019

0.467

Compound

-0.029

0.533

Cispl. × Comp.

-0.056

0.134

Data from 3 independent experiments were modeled as (Viability = Constant + Cisplatin + Compound + Cisplatin* Compound) to analyze
effects of Cisplatin, Compound, and Cisplatin-Compound interactions. Tabulated are standardized coefficients (B) with corresponding p
values (Sig.) for each model. The goodness of fit, R2, is also listed for each model.
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Figure 2 Kaempferol and/or cisplatin's effect on ABCC1, ABCC5, ABCC6, NFκB1, cMyc and CDKN1A mRNA levels. OVCAR-3 cells (5 × 105) were
seeded in 60-mm cell culture dishes and incubated for 16 hours before chemical treatment (0, 40, and 80-μM cisplatin with or without 20-μM kaempferol) for another 24 hours. RNA was extracted with TRIzol Reagent and quantitated by qRT-PCR as described in Materials and Methods. Gene mRNA
levels were adjusted by GAPDH and expressed as percent of control. Data represents MEAN ± SE from 3 independent experiments. * p < 0.05 as compared to control by ANOVA Dunnett t test. ** p < 0.01 as compared to control by ANOVA Dunnett t test.

treatment. However, all of these effects were additive
except for kaempferol and α-tocopherol succinate.
To gain an insight into the mechanism of kaempferol
sensitization, the mRNA levels of ABCC1, ABCC5,
ABCC6, NFκB1, cMyc and CDKN1A genes were analyzed by qPCR. The levels of ABCC1, ABCC5, or NFκB1
were not influenced by cisplatin or kaempferol. With the
addition of kaempferol, cisplatin treatment significantly
inhibited ABCC6 and cMyc mRNA levels. Since ABCC6
is a membrane transport protein important in the reduction of intracellular accumulation of cisplatin [12], the
reduced amount of ABCC6 by kaempferol prevents the
removal of cisplatin from the cell leading to the killing of
the cancer cell by cisplatin.
Another mechanism of sensitization of cisplatin by kaempferol is through down regulating of cMyc and up regulation of CDKN1A. The proto-oncogene cMyc is highly
expressed in proliferating cells and is commonly activated
in human cancers [19]. cMyc is known to down regulate
the CDKN1A gene and our study showed a strong negative association between the two (Pearson correlation
coefficient, -0.649, p < 0.01). The up regulation of
CDKN1A usually leads to the apoptosis of the cancer
cells [20]. Our apoptosis assay showed that cisplatin alone
does not induce apoptosis of the ovarian cancer cells. The
addition of 20 μM kaempferol to the cisplatin treatment
induces the apoptosis of the cancer cells. Therefore, kae-

mpferol enhances the effect of cisplatin through down
regulation of cMyc in promoting apoptosis of ovarian
cancer cells.

Conclusions
Our work found that kaempferol works synergistically
with cisplatin in inhibiting ovarian cancer cell viability,
and their inhibition on cell viabilities was induced
through inhibiting ABCC6 and cMyc gene transcription.
Apoptosis assay showed the addition of 20 μM kaempferol to the cisplatin treatment induces the apoptosis of
the cancer cells. Therefore, kaempferol enhances the
effect of cisplatin through down regulation of cMyc in
promoting apoptosis of ovarian cancer cells. As a dietary
component, kaempferol sensitizes ovarian cancer cells to
cisplatin treatment and deserves further studies for possible applications in chemotherapy of ovarian cancers.
Methods
Chemicals

All 11 chemicals, including cisplatin, 2 α-tocopherols,
and 8 flavonoids were obtained from Sigma (St. Louis,
MO). Chemicals were dissolved in DMSO to form a 20mM stock solution which were stored at -20°C. For cell
treatment, DMSO concentrations were controlled constant through various concentration and chemical combinations.

Luo et al. Cancer Cell International 2010, 10:16
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Figure 3 Negative correlation between cMyc and CDKN1A gene mRNA levels. The mRNA levels of CDKN1A and cMyc from 3 independent experiments were expressed as percent and plotted against each other for Pearson Correlation analysis. A strong negative association exits for CDKN1A
and cMyc genes (as regulated by cisplatin treatment) regardless of kaempferol treatment.

Cell Culture

The human ovarian cancer cell line OVCAR-3 was
obtained from American Type Culture Collection
(Manassas, VA). Cells were cultured in RPMI 1640
medium supplemented with 4 μmol/mL glutamine, 100
units/mL penicillin, 100 μg/mL streptomycin (VWR,
West Chester, PA), and 10% US-qualified fetal bovine
serum (Invitrogen, Grand Island, NY) in a humidified
incubator with 5% CO2 at 37°C.
Cell Proliferation Assay

Chemical effects on OVCAR-3 cell proliferation were colorimetrically determined with a "CellTiter 96® Aqueous
One Solution Cell Proliferation Assay" kit from Promega
(Madison, WI). OVCAR-3 cells (8 × 103) were seeded into
wells in 96-well cell culture microplates and incubated for
16 hours. Chemical treatments (0, 40, and 80-μM Cisplatin with other chemicals of 0, or 20-μM) were then
applied in triplicates for another 24 hours. After removal
of medium, 100 μL freshly-prepared Aqueous One Solution (MTS tetrazolium compound) was added to each
well, incubated at 37°C for 2 hours, and optical density
(OD) measured at 490 nm with a microplate reader (BioRad, Hercules, CA). A linear standard curve was gener-

ated by seeding different numbers of cells (0 - 1 × 104) at
the beginning and used to quantify chemical-treated cells'
viability. Cell viability was expressed as percent of control
(0-μM cisplatin and 0-μM other chemicals), and averaged
from replicates. Data from 3 independent experiments
were pooled for statistical analysis.
Quantification of mRNA levels for ABCC1, ABCC5, ABCC6,
NFκB1, cMyc and CDKN1A genes

Effect on transcription of the 6 genes' were determined by
quantitative reverse-transcription Polymerase Chain
Reaction (qRT-PCR). OVCAR-3 cells (5 × 105) were
seeded in 60-mm cell culture dishes and incubated for 16
hours before chemical treatment (0, 40, and 80-μM cisplatin with or without 20-μM kaempferol) for another 24
hours. Cells were washed twice with PBS (Phosphate
Buffered Saline), and RNA was extracted with TRIzol
Reagent (Invitrogen, Grand Island, NY). RNA was resuspended in DEPC (diethyl pyrocarbonate)-treated water
and introduced to reverse transcription with oligo-dT
and AMV Reverse Transcriptase from Promega (Madison, WI). Real-time PCR was deployed to amplify cDNA
for the 6 genes with RT2 SYBR Green qPCR Master Mix
(SuperArray Bioscience, Frederick, MD) and a Chromo4

Luo et al. Cancer Cell International 2010, 10:16
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Figure 4 Effects in inducing caspase-3 levels in OVCAR-3 cancer cells. OVCAR-3 cells (2 × 106) were seeded in 60-mm dishes, incubated for 16
hours, and treated with kaempferol (0 or 20 μM) and cisplatin (0, 40, and 80 μM) for 2 hours. Caspase-3 levels were determined with a colorimetric
assay kit and normalized to total protein levels determined with a BCA assay kit. Normalized caspase-3 levels were expressed as percent of control,
logged and fitted to linear regression models to check cisplatin and kaempferol's effects on cell apoptosis, and their interactions. Data represents
MEAN ± SE from 4 independent experiments. * p < 0.05 as compared to control by ANOVA Dunnett t test. ** p < 0.01 as compared to control by ANOVA
Dunnett t test.

real-time detector coupled to a DNA Engine thermal
cycler (Bia-Rad, Hercules, CA). Primers for CDKN1A
were designed from the Primer3 website http://
frodo.wi.mit.edu/primer3/ to amplify both transcript
variants, and primers for other genes were chosen from
the PrimerBank website http://pga.mgh.harvard.edu/
primerbank/ (Table 2). The PCR program was set as follow: 95°C 10'; (95°C 20", 58°C 45", 72°C 20", 77°C 1", read
plate) × 50; 72°C 5'; 58°C 1'; melting curve (65°C -95°C by
0.5°C increments). A standard curve was generated from
series dilutions of PCR products to monitor amplification
efficiency, and to relatively quantify samples for every
gene. RNA samples without reverse transcription served
as non-reverse-transcription (-RT) controls, and melting
curves were checked for uniform amplification. In processing amplification curves, baselines were set as average levels through cycle 2-12, and threshold values was
set as 0.01. Gene expression levels, as relatively quantified
by individual standard curves, were further adjusted by

GAPDH (Glyceraldehyde 3-phosphate dehydrogenase)
levels, and expressed as percent of control (0-μM cisplatin and 0-μM kaempferol). Data from 3 independent
experiments were pooled for statistical analysis.
Apoptosis Assay

Cell apoptosis was determined by measuring caspase-3
levels with a Caspase-3 Colorimetric Assay Kit (R&D Systems, Minneapolis, MN) and total protein levels with a
BCA (bicinchoninic acid) Protein Assay Kit (Pierce Biotechnology, Rockford, IL). Cells (2 × 106) were seeded in
60-mm dishes and incubated 16 hours before being
treated with kaempferol (0 or 20 μM) and cisplatin (0, 40,
and 80 μM) for 2 hours. After 3 washes with cold PBS,
cells were harvested in lysis buffer, and cell lysates were
collected for caspase-3 assay and for the BCA assay as per
instructions. Standard curves were generated by serial
dilution of recombinant human caspase-3 (R&D Systems)
and albumin standards (2 mg/mL), and caspase-3 levels

Luo et al. Cancer Cell International 2010, 10:16
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Table 2: Primer sequences for genes analyzed.
Gene

GenBank Accession

Primers

Amplicon size

GAPDH

NM_002046

CAT GAG AAG TAT GAC AAC AGC CT

113

AGT CCT TCC ACG ATA CCA AAG T
ABCC1

NM_004996

CCA GTG GGG ATC GGA CAG A

124

AGG GGA TCA TCG AAG AGG TAA AT
ABCC5

NM_005688

CCA GGG TCC TGA TTC GGG A

122

CTC CTG CCC TTT ATT GTA GGC
ABCC6

NM_001171

AGC CAG CTA CTC GTC TGT CT

108

CGA GCA TTG TTC TGA GCC A
NFkB1

NM_003998

ATT TGA AAC ACT GGA AGC ACG A

145

GCG GAT TAG CTC TTT TTC CCG
cMyc

NM_002467

TCG GAA GGA CTA TCC TGC TG

133

GTG TGT TCG CCT CTT GAC ATT
CDKN1A

NM_000389

TTA GCA GCG GAA CAA GGA GT

226

AGC CGA GAG AAA ACA GTC CA

were normalized to total protein levels for each sample.
Normalized caspase-3 levels were expressed as percent of
control and logged for linear regression analysis. A total
of 4 independent experiments were performed for statistical analysis.

co-treatment with compound: two lines that depart from
each other when moving toward higher cisplatin concentrations. The relationship between cMyc and CDKN1A
genes' mRNA levles was evaluated by Pears' Correlation
Analysis in SPSS software.

Statistical Analysis

Declaration of Competing interests
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All data were normalized as percent of control within
each experiment and data from several independent
experiments were pooled to represent three biological
replicates. For mRNA levels and caspase-3 levels, treatment groups with various concentrations of cisplatin
and/or kaempferol were compared against control by
ANOVA with Dunnett t multiple comparisons in SPSS
15.0 software (SPSS Inc, Chicago, IL). For detection of
interactions between cisplatin and compounds, cell viability levels and caspase-3 levels (at logarithmic scale)
were plotted against cisplatin (coded as 0, 1, 2 to represent 0, 40, and 80 μM cisplatin, respectively) with or without 20-μM test chemical (coded as 0, 1) for linear
regression analysis in SPSS 15.0 software. Cisplatin, compound, and the product between cisplatin and compound
were entered as 3 predictors for linear regression analysis
to examine the effects of cisplatin, compound, and cisplatin-compound interaction, respectively (Y = Constant +
Cisplatin + Compound + Cisplatin*Compound). An additive effect between cisplatin and compound will give two
lines nearly parallel, while an interaction will have unparallel lines and a significant coefficient for the product predictor: Cisplatin*Compound. A sensitization effect can
be seen when there is an interaction between cisplatin
and compound and the effect of cisplatin is amplified by
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